PH domain and leucine rich repeat protein phosphatase 1Genealiases: PHLPP · PLEKHE1 · PPM3A · SCOP
Q-omics provides the consensus-scored PHLPP1 profile across patient tissues and cancer cell-line models. PHLPP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PHLPP1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PHLPP1 RNA expression shows 20,795 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where PHLPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHLPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHLPP1 survival associations across molecular data types. PHLPP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHLPP1 RNA expression–survival associations across cancer types. High PHLPP1 expression shows unfavorable associations in MESO and ACC, but favorable associations in KIRC, HNSC, LGG and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PHLPP1 RNA expression.
This table summarizes PHLPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PHLPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHLPP1 shows lower tumor expression in KIRC, THCA, BRCA and KIRP and higher tumor expression in LUSC and LUAD. The KIRC box plot shows higher PHLPP1 RNA expression in normal versus tumor tissue (log2 FC = −0.657, t-test p < 0.001).
This table shows molecular features associated with PHLPP1 in patient tissues and cancer cell lines. In patient samples, PHLPP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHLPP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
